natgillin/translations-raw huggingface dataset:
The absorption of nelfinavir may be reduced in situations where the gastric pH is increased irrespective of cause.
Absorpcija nelfinavirja se lahko zmanjša, če se poveča želodčni pH, neglede na vzrok.
Children with weights between 10.5-12 kg, 12-14 kg and 18-22 kg will receive a different number of tablets with each meal.
Otroci s telesno maso 10,5-12 kg, 1214 kg in 18-22 kg bodo ob vsakem obroku prejeli različno število tablet.
• Pimozide (used for mental health problems)
• pimozid (za psihične težave),
If nelfinavir is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Če se nelfinavir daje sočasno s parenteralno obliko midazolama, se mora to izvesti v enoti za intenzivno nego ali podobnem okolju, ki zagotavlja natančno klinično spremljanje in ustrezno medicinsko oskrbo v primeru respiratorne depresije in/ali podaljšane sedacije.
Serious and non-serious adverse reactions from post-marketing spontaneous reports (where nelfinavir was taken as the sole protease inhibitor or in combination with other antiretroviral therapy), not mentioned previously in section 4.8, for which a causal relationship to nelfinavir cannot be excluded, are summarised below.
Resni in neresni neželeni učinki iz spontanega poročanja v obdobju trženja zdravila (nelfinavir uporabljan kot edini zaviralec proteaze ali v kombinaciji z drugimi protiretrovirusnimi zdravili), ki v predhodno navedenih neželenih učinkih v poglavju 4.8 niso omenjeni, so povzeti spodaj.
Renal and hepatic impairment: there are no data specific for HIV positive patients with renal impairment and therefore specific dosage recommendations cannot be made (see section 4.4).
Ledvična in jetrna okvara: za HIV pozitivne bolnike z ledvično okvaro podatkov ni na voljo, zato posebnih priporočil o odmerjanju ni (glejte poglavje 4.4).
Combination with other medicinal products: Caution is advised whenever VIRACEPT is coadministered with agents that are inducers or inhibitors and/or substrates of CYP3A4; such combinations may require dose adjustment (see also sections 4.3 and 4.8).
Kombinacija z drugimi zdravili: previdnost je potrebna pri jemanju zdravila VIRACEPT skupaj z snovmi, ki so induktorji ali zaviralci, in/ali substrati za CYP3A4; takšne kombinacije lahko potrebujejo prilagoditev odmerka (glejte tudi poglavji 4.3 in 4.8).
• When your child weighs 18 kg or less, you must provide the tablets three times a day.
• Kadar vaš otrok tehta 18 kg ali manj, mu morate dati tablete trikrat na dan.
Nelfinavir was found to be active against a broad range of laboratory strains and clinical isolates of HIV-1 and the HIV-2 strain ROD.
Nelfinavir je bil učinkovit proti širokemu obsegu laboratorijskih linij in kliničnih izolatov HIV-1 in HIV-2 linij ROD.
Proportion of patients with HIV RNA below LOQ (sensitive and ultrasensitive assays) at Week 48 Assay
Delež bolnikov s HIV RNA pod mejo detekcije (občutljive in zelo občutljive metode) v 48. tednu Metoda
Patients older than 13 years: VIRACEPT 250 mg tablets are recommended for adults and older children (see Summary of Product Characteristics for VIRACEPT 250 mg tablets).
Bolniki, starejši od 13 let: tablete VIRACEPT 250 mg so priporočljive za odrasle in starejše otroke (glejte Povzetek glavnih značilnosti za tablete VIRACEPT 250 mg).
Elimination: oral clearance estimates after single doses (24-33 l/h) and multiple doses (26-61 l/h) indicate that nelfinavir exhibits medium to high hepatic bioavailability.
Izločanje: ocene očistka po peroralnih enkratnih odmerkih (24 do 33 l/h) in večkratnih odmerkih (26 do 61 l/h) nakazujejo srednje do veliko biološko uporabnost nelfinavirja v jetrih.
Once dispersed, the cloudy bluish liquid should be thoroughly mixed and consumed immediately.
Po raztopitvi, je treba motno modrikasto tekočino temeljito premešati in takoj zaužiti.
For adults or children unable to take tablets, Viracept tablets may be put into water and taken as follows:
Odrasli ali otroci, ki ne morejo pogoltniti tablet, lahko Viracept raztopijo v vodi na naslednji način:
• Put the tablets in a half cup of water and stir with a spoon.
• tableto dajte v pol kozarca vode in premešajte z žlico,
The following side effects may happen with this medicine.
Pri uporabi tega zdravila se lahko pojavijo naslednji neželeni učinki.
Cmax fold increase Increase in Tmax (hr)
Povečanje Tmax (h)
Pharmacotherapeutic group:direct acting antivirals, ATC code: J05AE04.
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij; Oznaka ATC: J05AE04.
There are not sufficient data from patients with liver impairment and therefore specific dose recommendations cannot be made (see section 5.2).
Ustreznih podatkov za bolnike z jetrno okvaro ni, zato ni posebnih priporočil o odmerjanju (glejte poglavje 5.2).
• Low numbers of a type of white blood cell that fights infections (neutrophils).
• zmanjšano število belih krvnih celic, ki se borijo proti okužbam (nevtrofilci),
If you have haemophilia type A or B, in rare cases your bleeding may increase.
Če imate hemofilijo tipa A ali B, se lahko v redkih primerih krvavitev poveča.
Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered
Razmisliti je treba o prilagoditvi odmerka midazolama, zlasti, če je bil dan več kot en odmerek midazolama.
The difference between morning and afternoon or evening trough concentrations for the TID and BID regimens was also observed in healthy volunteers who were dosed at precise 8- or 12-hour intervals.
Razliko med jutranjimi in popoldanskimi ali večernimi najnižjimi koncentracijami pred naslednjim odmerkom pri odmerjanju dvakrat in trikrat na dan so opazili tudi pri zdravih prostovoljcih, ki so prejeli odmerek v točno določenih 8- ali 12- urnih intervalih.
• Warfarin (for lowering the chance of blood clots in your body)
• varfarin (za zmanjševanje zlepljanja krvnih ploščic v vašem telesu),
If you have haemophilia type A or B, in rare
Če imate hemofilijo tipa A ali B, se lahko v redkih
Antiviral activity in vitro: the antiviral activity of nelfinavir in vitro has been demonstrated in both HIV acute and chronic infections in lymphoblastoid cell lines, peripheral blood lymphocytes and monocytes/macrophages.
Protivirusna aktivnost in vitro: protivirusno aktivnost nelfinavirja in vitro so ugotovili tako v akutnih kot tudi v kroničnih okužbah s HIV v limfoblastoidnih celičnih linijah, limfocitih periferne krvi in monocitih/makrofagih.
Concomitant use of protease inhibitors with lovastatin or simvastatin is contraindicated.
Sočasna uporaba zaviralcev proteaz z lovastatinom ali simvastatinom je kontraindicirana.
In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Pri nekaterih bolnikih z napredovalo okužbo s HIV in z oportunistično okužbo v anamnezi se lahko kmalu po začetku anti-HIV zdravljenja pojavijo znaki in simptomi vnetja povezani s prejšnjimi okužbami.
This medicinal product must not be mixed with acidic substances due to taste (see section 4.2).
Zdravila zaradi okusa ne smemo mešati s kislimi snovmi (glejte poglavje 4.2).
Among other things, very large doses of Viracept might cause problems with your heart rhythm.
Poleg drugih simptomov, lahko zelo veliki odmerki zdravila Viracept povzročijo motnje srčnega ritma.
Treatment with Viracept does not stop you giving HIV to others through contact with blood or sexual contact.
Zdravljenje z zdravilom Viracept ne preprečuje prenosa virusa HIV na druge osebe z okuženo krvjo ali spolnim stikom.
Driving and using machines Viracept is not likely to affect you being able to drive or use any tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Viracept verjetno ne vpliva na sposobnost vožnje ali upravljanja z orodji ali s stroji.
If you have been told by your doctor that you cannot tolerate or digest some sugars (have an intolerance to some sugars), talk to your doctor before taking this medicine.
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Patients received VIRACEPT either three times daily or twice daily with food or with meals.
Bolniki so prejemali zdravilo VIRACEPT bodisi trikrat na dan ali dvakrat na dan s hrano ali z obroki.
Nevirapine
nevirapin
Decreases in HIV RNA observed with nelfinavir monotherapy were less pronounced and of shorter duration.
Zmanjšanje HIV RNA pri monoterapiji z nelfinavirjem je bilo manj izrazito in krajše.
Therefore the potential for QT prolongation should be considered in cases of overdose (see section 4.9).
Zato je pri prevelikem odmerjanju treba upoštevati možnost Q-T podaljšanja (glejte poglavje 4.9).
Viracept is not a cure for HIV infection.
Zdravilo Viracept ne ozdravi okužbe z virusom HIV.
HIV isolates from selected patients treated with nelfinavir alone or in combination with reverse transcriptase inhibitors were monitored for phenotypic (n=19) and genotypic (n=195, 157 of which were assessable) changes in clinical trials over a period of 2 to 82 weeks.
HIV izolate izbranih bolnikov, zdravljenih z nelfinavirjem samim ali v kombinaciji z zaviralci reverzne transkriptaze, so proučevali glede na fenotipske (n = 19) in genotipske (n = 195, od tega je bilo ocenljivih 157) spremembe v kliničnih preskušanjih, ki so potekale v obdobju od 2 do 82 tednov.
Trough drug exposures remain at least twenty fold greater than the mean IC95 throughout the dosing interval for both regimens.
Najnižja izpostavljenost zdravilu tik pred ponovnim odmerkom je bila vsaj dvajsetkrat večja kot srednja IC95 skozi celoten dozirni interval za obe shemi odmerjanja.
The majority of patients in these studies received either 750 mg TID either alone or in combination with nucleoside analogues or 1250 mg BID in combination with nucleoside analogues.
Večina bolnikov v teh študijah je prejela 750 mg trikrat na dan, bodisi samega ali v kombinaciji z nukleozidnimi analogi, ali 1250 mg dvakrat na dan v kombinaciji z nukleozidnimi analogi.
Only 1-2 % of the dose was recovered in urine, of which unchanged nelfinavir was the major component.
Le 1 do 2 % odmerka se izloči z urinom, največ kot nespremenjeni nelfinavir.
• Ask your doctor or pharmacist for advice before taking any medicine.
• Posvetujte se z zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
The effects of nelfinavir (alone or combined with other antiretroviral agents) on biological markers of disease activity, CD4 cell count and viral RNA, were evaluated in several studies involving HIV-1 infected patients.
Učinke nelfinavirja (samega ali kombiniranega z drugimi protiretrovirusnimi učinkovinami) na biološke označevalce aktivnosti bolezni, število celic CD4 in virusno RNA, so proučevali v številnih študijah, ki so vključevale bolnike, okužene s HIV-1.
The estimated volumes of distribution in both animals and humans is 2-7 l/kg which exceeded total body water and suggests extensive penetration of nelfinavir into tissues.
Pri živalih in ljudeh so ocenjeni volumni porazdelitve (2 do 7 l/kg) presegali volumen celotne telesne tekočine, kar nakazuje obsežno prehajanje nelfinavirja v tkiva.
Powder with milk, formula, pudding, or water, as part of a light meal or tablet taken with a light meal
Prašek z mlečno formulo, pudingom ali vodo, kot del lahkega obroka, ali tableta zaužita z lahkim obrokom
Therapy with VIRACEPT should be initiated by a physician experienced in the management of HIV infection.
Zdravljenje z zdravilom VIRACEPT mora vpeljati zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Physicians should not use potent inducers of CYP 3A4 in combination with Viracept and should consider using alternatives when a patient is taking VIRACEPT (see section 4.5).
Zdravniki ne smejo uporabiti močnih induktorjev CYP3A4 v kombinaciji z zdravilom Viracept in morajo razmisliti o drugih možnostih zdravljenja, če bolnik jemlje zdravilo VIRACEPT (glejte poglavje 4.5).
Treatment emergent NRTI resistance was significantly less frequent with fosamprenavir/ritonavir compared to nelfinavir (13 % versus 57 %; p<0.001).
Odpornost proti potrebnemu zdravljenju z nukleozidnimi analogi zaviralcev reverzne transkriptaze (nucleoside analogue reverse transcriptase inhibitors - NRTI) je bilo značilno manj pogosto pri fosamprenavirju/ritonavirju v primerjavi z nelfinavirjem (13 % v primerjavi s 57 %; p < 0,001).
Clinical isolates (n=5) with decreased susceptibility to zidovudine, lamivudine, or nevirapine remain fully susceptible to nelfinavir in vitro.
Klinični izolati (n = 5) z zmanjšano občutljivostjo za zidovudin, lamivudin ali nevirapin ostajajo in vitro povsem občutljivi za nelfinavir.
• Medicines that lower stomach acid such as lansoprazole
• zdravila, ki zavirajo izločanje želodčne kisline, kot je lansoprazol,
Pregnancy, contraception and breast-feeding • Talk to your doctor before you take Viracept if you are pregnant or planning to become
Nosečnost, kontracepcija in dojenje • Če ste noseči ali nameravate zanositi, o tem obvestite svojega zdravnika preden začnete jemati
The cleavage of these viral polyproteins is essential for the maturation of infectious virus.
Cepitev virusnih polibeljakovin je bistvena za zorenje infektivnega virusa.
For younger children able to take tablets, Viracept tablets may be taken instead of the oral powder.
Mlajšim otrokom, ki lahko jemljejo tablete, lahko namesto peroralnega praška dajemo tablete zdravila Viracept.
Pharmacokinetics of nelfinavir after a single dose of 750 mg was studied in patients with liver impairment and healthy volunteers.
Farmakokinetika nelfinavirja po enkratnem odmerku 750 mg je bila proučevana pri bolnikih z jetrno okvaro in zdravih prostovoljcih.
VIRACEPT should not be co-administered with omeprazole due to a reduction in exposure to nelfinavir and its active metabolite M8 (Tert-butyl hydroxy nelfinavir).
Zdravila VIRACEPT ne smemo sočasno jemati z omeprazolom zaradi zmanjšane izpostavljenosti nelfinavirju in njegovemu aktivnemu presnovku M8 (terc-butil hidroksinelfinavir).
Cross-resistance between nelfinavir and reverse transcriptase inhibitors is unlikely because different enzyme targets are involved.
Navzkrižna odpornost med nelfinavirjem in zaviralci reverzne transkriptaze je zaradi različnih tarčnih encimov malo verjetna.
Summary of Steady-state AUC24 of nelfinavir in Paediatric Studies
Povzetek AUC24 nelfinavirja v stanju dinamičnega ravnovesja pri pediatričnih študijah
Median baseline HIV-1 RNA was 4.8 log10 copies/ml in both treatment groups.
Mediana začetne vrednosti HIV-1 RNK je bila 4,8 log10 kopij/ml v obeh skupinah.
The weight of evidence indicates that nelfinavir is unlikely to be a carcinogen in humans.
Glede na rezultate raziskave je zelo malo verjetno, da bi bil nelfinavir za ljudi karcinogen.
Some patients taking combination anti-retroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Pri nekaterih bolnikih, ki jemljejo kombinirano protiretrovirusno zdravljenje, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva zaradi nezadostne prekrvitve kosti).
HMG-CoA reductase inhibitors (statins): HMG-CoA reductase inhibitors may interact with protease inhibitors and increase the risk of myopathy, including rhabdomyolysis.
Zaviralci reduktaze HMG-CoA (statini): zaviralci reduktaze HMG-CoA lahko medsebojno delujejo z zaviralci proteaz in povečajo tveganje za miopatijo, vključno z rabdomiolizo.
Nelfinavir exposure increases with increasing calorie or fat content of meals taken with VIRACEPT.
Izpostavljenost nelfinavirju narašča s povečanjem števila kalorij ali vsebnostjo maščob v obroku, ki se zaužije skupaj z zdravilom VIRACEPT.
Osteonecrosis: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART - combination antiretroviral therapy).
• You have a rare blood problem which runs in families called ‘haemophilia'.
• imate redko dedno bolezen krvi, ki se imenuje »hemofilija«,
• When your child weighs 18 kg or more, you may provide the tablets either two or three times a day.
• Kadar vaš otrok tehta 18 kg ali več, mu lahko date tablete dvakrat ali trikrat na dan.
It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present
Menijo, da so ti simptomi posledica izboljšanja telesnega imunskega odgovora, ki omogoča telesu, da se brani pred okužbami, ki so bile prej prisotne brez
• Rifabutin, erythromycin or clarithromycin (for bacterial infections)
• rifabutin, eritromicin ali klaritromicin (za bakterijske okužbe),
If you stop taking Viracept
Če ste prenehali jemati zdravilo Viracept
Administration of 300 mg/kg/day resulted in an increased incidence of thyroid follicular cell adenoma.
Dajanje 300 mg/kg/dan je povzročilo porast pogostnosti folikularnega celičnega adenoma ščitnice.
Nelfinavir is also an inhibitor of CYP 3A4.
Nelfinavir je tudi zaviralec CYP 3A4.
The use of nelfinavir in patients with moderate hepatic impairment has not been studied.
Uporabe nelfinavirja pri bolnikih z zmerno jetrno okvaro niso proučevali.
The pharmacokinetic properties of nelfinavir have been evaluated in healthy volunteers and HIV-infected patients.
Farmakokinetične lastnosti nelfinavirja so proučevali pri zdravih prostovoljcih in pri s HIV okuženih bolnikih.
A total of approximately 400 patients received nelfinavir in paediatric treatment trials (Studies 524, 556, PACTG 377/725, and PENTA-7) for up to 96 weeks.
V študijah zdravljenja pediatričnih bolnikov (študije 524, 556, PACTG 377/725 in PENTA-7) je nelfinavir v celoti prejemalo približno 400 bolnikov do 96 tednov.
The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Kombinacija lahko povzroči povečano tveganje za kardiovaskularne neželene dogodke, povezane s salmeterolom, vključno z podaljšanim QT, palpitacijami in sinusno tahikardijo.
• White 1 gram (1g) scoop.
• Bela merica po 1 gram (1 g).
Carcinogenicity: Two year oral carcinogenicity studies with nelfinavir mesilate were conducted in mice and rats.
Karcinogenost: pri miših in podganah so izvedli dvoletne študije karcinogenosti s peroralnim nelfinavirjevim mesilatom.
Increased alanine aminotransferase, increased aspartate aminotransferase, neutropenia, blood creatinine phosphokinase increased, neutrophil count decreased
Preiskave pogosti povečana alanin aminotransferaza, povečana aspartat aminotransferaza, nevtropenija, povečana keratinin fosfokinaza, znižano število nevtrofilcev
Concomitant use of sildenafil prescribed for the treatment of pulmonary arterial hypertension with VIRACEPT is contraindicated (see section 4.3).
Sočasna uporaba sildenafila, predpisanega za zdravljenje pljučne arterijske hipertenzije, z zdravilom VIRACEPT je kontraindicirana (glejte poglavje 4.3).
The glass should be rinsed with a half cup of water and the rinse should be swallowed to ensure that the entire dose is consumed.
Kozarec je treba poplakniti s pol kozarca vode in jo popiti, saj s tem zagotovimo, da se zaužije celoten odmerek.
Do not stop taking this medicine without talking to your doctor first.
Zdravila ne smete prenehati jemati brez predhodnega posvetovanja z vašim zdravnikom.
This helps your body to get the full benefit from your
Na ta način bo vaše telo dobilo največ koristi od
Patients with chronic hepatitis B or C and treated with anti-retroviral agents are at increased risk for severe and potentially fatal liver adverse events and may require blood tests for control of liver function.
Pri bolnikih s kroničnim hepatitisom B ali C, ki se zdravijo s protiretrovirusnimi zdravili, obstaja zvečano tveganje za hude in potencialno smrtne jetrne neželene dogodke, zato bodo morda potrebni krvni testi za nadzor jetrnega delovanja.
144 g Oral powder
144 g peroralnega praška
Adverse reactions from clinical trials with nelfinavir
Neželeni učinki iz kliničnih študij z nelfinavirjem
Viracept TID (%)
Viracept trikrat na dan (%)
Combination of simvastatin or lovastatin and nelfinavir is contraindicated (see contraindication).
Kombinacija simvastatina ali lovastatina in nelfinavirja je kontraindicirana (glejte kontraindikacije).
• The active substance in Viracept is nelfinavir.
• Zdravilna učinkovina zdravila Viracept je nelfinavir.
An HIV isolate obtained from a patient receiving saquinavir therapy showed decreased susceptibility to saquinavir (7- fold) but did not demonstrate a concordant decrease in susceptibility to nelfinavir.
Pri izolatu HIV, ki so ga pridobili od bolnika, ki je prejemal zdravljenje s sakvinavirjem, so opazili zmanjšano občutljivost za sakvinavir (7-krat), niso pa opazili zmanjšane občutljivosti za nelfinavir.
• Ketoconazole, itraconazole or fluconazole (for fungal infections)
• ketokonazol, itrakonazol ali flukonazol (za glivične okužbe),
In vivo: The overall incidence of the D30N mutation in the viral protease of assessable isolates (n=157) from patients receiving nelfinavir monotherapy or nelfinavir in combination with zidovudine and lamivudine or stavudine was 54.8 %.
In vivo: skupna incidenca mutacije D30N virusne proteaze ocenljivih izolatov (n = 157) bolnikov, ki so prejemali samostojno zdravljenje z nelfinavirjem ali nelfinavir v kombinaciji z zidovudinom in lamivudinom ali stavudinom, je bila 54,8 %.
These may include loss of fat from legs, arms and face, increased fat in the abdomen (belly) and other internal organs, breast enlargement and fatty lumps on the back of the neck (‘buffalo hump').
Spremembe lahko zajemajo izgubo maščevja na nogah, rokah in obrazu, povečanje maščevja v abdomnu (trebuhu) in drugih notranjih organih, povečanje prsi in maščobne kepe na zadnjem delu vratu (bivolja grba).
Clinical pharmacodynamic data: treatment with nelfinavir alone or in combination with other antiretroviral agents has been documented to reduce viral load and increase CD4 cell counts in HIV-1 seropositive patients.
Klinični farmakodinamični podatki: zdravljenje s samim nelfinavirjem ali v kombinaciji z drugimi protiretrovirusnimi učinkovinami dokazano zmanjšuje virusno obremenitev in poveča število celic CD4 pri HIV-1 seropozitivnih bolnikih.
PDE5 inhibitors: particular caution should be used when prescribing sildenafil, tadalafil or vardenafil for the treatment of erectile dysfunction in patients receiving VIRACEPT.
Zaviralci PDE-5: pri predpisovanju sildenafila, tadalafila ali verdenafila za zdravljenje erektilne disfunkcije pri bolnikih, ki prejemajo zdravilo VIRACEPT, je potrebna posebna previdnost.
Neutropenia/leukopenia was the most frequently observed laboratory abnormality.
Najpogosteje opažena laboratorijska nenormalnost je bila nevtropenija/levkopenija.
Excipients: - Contains sucrose palmitate: 10.0 mg per gram of oral powder.
Pomožne snovi: - vsebuje saharozo palmitat: 10,0 mg na gram peroralnega praška.
Of 19 patients for whom both phenotypic and genotypic analyses were performed on clinical isolates, 9 patients isolates showed reduced susceptibility (5- to 93-fold) to nelfinavir in vitro.
Od 19 bolnikov, za katere so na kliničnih izolatih opravili fenotipske in genotipske analize, se je pri 9 izolatih bolnikov pokazala zmanjšana občutljivost (5- do 93-krat) na nelfinavir v in vitro.